Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.

Neves JS, Vasques-Nóvoa F, Borges-Canha M, Leite AR, Sharma A, Carvalho D, Packer M, Zannad F, Leite-Moreira A, Ferreira JP

Diabetes, obesity & metabolism21 Sept 2022Cited by 76 (Europe PMC)

PMID36082522PMCIDPMC9742170DOI10.1111/dom.14862PepBankPUB-36082522

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with HFrEF, liraglutide showed a non-significant trend toward more total HF hospitalizations or all-cause deaths than placebo.
In plain wordsIn people with heart failure, liraglutide showed a trend toward more hospital stays or deaths than placebo, but this was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeTotal HF hospitalizations or all-cause death
Study
n = 300
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
IRR
1.41 ratio
HF hospitalizations or death
Source sentences
Summary
The main outcome of the present analysis was total events of hospitalizations for heart failure (HF) or all-cause death.
2 context sentences(design, population, supporting numbers)
Summary · context
Compared to placebo, there was a trend towards increased risk with liraglutide of total HF hospitalizations or all-cause deaths (96 vs. 143 events, incidence rate ratio [IRR] 1.41, 95% confidence interval [CI] 0.98-2.04; P = 0.064) and total arrhythmias (21 vs. 39, IRR 1.76, 95% CI 0.92-3.37; P = 0.088).
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252201
02HumanRandomized controlled trialSafety outcome
In patients with HFrEF, liraglutide showed a non-significant trend toward more total arrhythmias than placebo.
In plain wordsIn people with heart failure, liraglutide showed a trend toward more heart rhythm problems than placebo, but this was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeTotal arrhythmic events
Study
n = 300
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
IRR
1.76 ratio
total arrhythmias
Source sentences
Summary
Secondary outcomes included total arrhythmic events and prespecified total events of interest (arrhythmias, sudden cardiac death, acute coronary syndrome, worsening HF, cerebrovascular event, venous thromboembolism, lightheadedness, presyncope/syncope or worsening renal function).
2 context sentences(design, population, supporting numbers)
Summary · context
Compared to placebo, there was a trend towards increased risk with liraglutide of total HF hospitalizations or all-cause deaths (96 vs. 143 events, incidence rate ratio [IRR] 1.41, 95% confidence interval [CI] 0.98-2.04; P = 0.064) and total arrhythmias (21 vs. 39, IRR 1.76, 95% CI 0.92-3.37; P = 0.088).
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252202
03HumanRandomized controlled trialSafety outcome
In patients with HFrEF, total prespecified events of interest were higher with liraglutide than with placebo.
In plain wordsIn people with heart failure, liraglutide was linked to more of the listed heart-related events than placebo.
Peptide
Liraglutide
Outcome
IncreaseTotal prespecified events of interest
Study
n = 300
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
IRR
1.43 ratio
prespecified events of interest
Source sentences
Summary
Total prespecified events of interest were increased with liraglutide compared to placebo (196 vs. 295, IRR 1.43, 95% CI 1.06-1.92; P = 0.018).
1 context sentence(design, population, supporting numbers)
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252203
04HumanRandomized controlled trialSafety outcome
In patients with HFrEF in NYHA Class III to IV, liraglutide was linked to a higher risk of HF hospitalization or all-cause death than placebo.
In plain wordsIn people with more severe heart failure, liraglutide was linked to more hospital stays or deaths than placebo.
Peptide
Liraglutide
Outcome
IncreaseHF hospitalization or death in NYHA Class III to IV
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
IRR
1.86 ratio
NYHA Class III to IV
Source sentences
Summary
The risk of HF hospitalizations or all-cause deaths with liraglutide was higher among patients in New York Heart Association (NYHA) Class III to IV (IRR 1.86, 95% CI 1.21-2.85) than in those in NYHA Class I to II (IRR 0.62, 95% CI 0.31-1.23; interaction P = 0.008), and among patients with diabetes (…
1 context sentence(design, population, supporting numbers)
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252204
05HumanRandomized controlled trialSafety outcome
In patients with HFrEF in NYHA Class I to II, liraglutide did not significantly change the risk of HF hospitalization or all-cause death versus placebo.
In plain wordsIn people with milder heart failure, liraglutide did not significantly change hospital stays or deaths compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHF hospitalization or death in NYHA Class I to II
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
IRR
0.62 ratio
NYHA Class I to II
Source sentences
Summary
The risk of HF hospitalizations or all-cause deaths with liraglutide was higher among patients in New York Heart Association (NYHA) Class III to IV (IRR 1.86, 95% CI 1.21-2.85) than in those in NYHA Class I to II (IRR 0.62, 95% CI 0.31-1.23; interaction P = 0.008), and among patients with diabetes (…
1 context sentence(design, population, supporting numbers)
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252205
06HumanRandomized controlled trialSafety outcome
In patients with HFrEF, the risk of HF hospitalization or all-cause death with liraglutide was higher among patients with diabetes, with a borderline interaction P value.
In plain wordsIn people with heart failure and diabetes, liraglutide was linked to a higher risk of hospital stays or deaths; the interaction was borderline.
Peptide
Liraglutide
Outcome
IncreaseHF hospitalization or death in patients with diabetes
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
Interaction P
0.051
diabetes
Source sentences
Summary
and among patients with diabetes (interaction P = 0.051).
1 context sentence(design, population, supporting numbers)
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252206
07HumanRandomized controlled trialSafety outcome
In patients with HFrEF, the risk of arrhythmic events with liraglutide was higher among patients without an implanted cardiac device.
In plain wordsIn people with heart failure but no implanted cardiac device, liraglutide was linked to more heart rhythm problems than placebo.
Peptide
Liraglutide
Outcome
IncreaseArrhythmic events in patients without an implanted cardiac device
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 180 days (follow-up)As given in this study (human).
Measurements
Interaction P
0.047
no implanted cardiac device
Source sentences
Summary
The risk of arrhythmic events was higher among those without an implanted cardiac device (interaction P = 0.047).
1 context sentence(design, population, supporting numbers)
Summary · context
FIGHT was a double-blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days.
Report a problemFND-3608252207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.